GlassScriptPhysician profile
Michael Alan Rogers
NPI 1407930555
$1,724.17
in general payments reported to CMS, 2019-2025
12 companies · $447 in 2025
The $447 reported for 2025 was more than what 92% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $143 · 2021: $244 · 2022: $183 · 2023: $265 · 2024: $260 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $971.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $971.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $248.61 | 2022-2025 | Azstarys |
| Pfizer INC. | $235.16 | 2019-2025 | |
| Glaxosmithkline, LLC. | $232.39 | 2019-2025 | Bexsero, Pediarix |
| Takeda Pharmaceuticals U.S.A., INC. | $230.43 | 2019-2022 | |
| Sanofi Pasteur INC. | $208.87 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $155.33 | 2019-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $154.69 | 2021-2024 | Vaxneuvance, Gardasil 9, Vaxelis |
| Tris Pharma INC | $109.07 | 2019-2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $51.27 | 2021-2024 | Qelbree |
| Neos Therapeutics, LP | $40.70 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $39.84 | 2025 | Jornay Pm |
| Seqirus USA INC | $17.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.